Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotide
The clinical potential of 111In and 90Y labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated Tyr3-octreotide (DOTA-TOC) have been reported in a number of publications, and Phase II clinical trials of 90Y-DOTA-TOC are currently in progress. However, to date, only a summary of...
Saved in:
Published in | Nuclear medicine communications Vol. 23; no. 5; p. 493 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
01.05.2002
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The clinical potential of 111In and 90Y labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated Tyr3-octreotide (DOTA-TOC) have been reported in a number of publications, and Phase II clinical trials of 90Y-DOTA-TOC are currently in progress. However, to date, only a summary of the large-scale preparation of these radiopharmaceuticals has been published. This publication aims to describe our experience of the small-scale synthesis of DOTA-TOC in the hope that this will assist others in the preparation of this and other similar radioconjugates. DOTA in the form of the tri-t-butyl ester was coupled to the Lys5 (BOC) protected Tyr3-octreotide in N,N-dimethylformamide or N-methyl-2-pyrolidinone, in a three-step reaction involving conjugation, using O-(7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and diisopropylethyamine (DIPEA) as coupling reagents, deprotection with trifluoroacetic acid and HPLC purification of the conjugates. The product was obtained in final yields of 60+/-5%. The purified product was characterized by mass spectroscopy, showing a molecular weight of 1421.55+/-0.08. In somatostatin receptor binding assays, the unlabelled DOTA-TOC showed an effective displacement of 99mTc labelled HYNIC-TOC (where HYNIC is hydrazinonicotinamide) (IC50=0.31+/-0.07 nm), confirming the retention of receptor-binding affinity. The conjugate could be efficiently labelled with 111In by addition of 111InCl3 and ammonium acetate buffer pH5 and heating (95 degrees C, 20 min). |
---|---|
AbstractList | The clinical potential of 111In and 90Y labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated Tyr3-octreotide (DOTA-TOC) have been reported in a number of publications, and Phase II clinical trials of 90Y-DOTA-TOC are currently in progress. However, to date, only a summary of the large-scale preparation of these radiopharmaceuticals has been published. This publication aims to describe our experience of the small-scale synthesis of DOTA-TOC in the hope that this will assist others in the preparation of this and other similar radioconjugates. DOTA in the form of the tri-t-butyl ester was coupled to the Lys5 (BOC) protected Tyr3-octreotide in N,N-dimethylformamide or N-methyl-2-pyrolidinone, in a three-step reaction involving conjugation, using O-(7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and diisopropylethyamine (DIPEA) as coupling reagents, deprotection with trifluoroacetic acid and HPLC purification of the conjugates. The product was obtained in final yields of 60+/-5%. The purified product was characterized by mass spectroscopy, showing a molecular weight of 1421.55+/-0.08. In somatostatin receptor binding assays, the unlabelled DOTA-TOC showed an effective displacement of 99mTc labelled HYNIC-TOC (where HYNIC is hydrazinonicotinamide) (IC50=0.31+/-0.07 nm), confirming the retention of receptor-binding affinity. The conjugate could be efficiently labelled with 111In by addition of 111InCl3 and ammonium acetate buffer pH5 and heating (95 degrees C, 20 min). |
Author | Edreira, M Mather, S J Melendez-Alafort, L |
Author_xml | – sequence: 1 givenname: M surname: Edreira fullname: Edreira, M organization: ICRF Nuclear Medicine Research Laboratory, St Bartholomew's Hospital, London, UK – sequence: 2 givenname: L surname: Melendez-Alafort fullname: Melendez-Alafort, L – sequence: 3 givenname: S J surname: Mather fullname: Mather, S J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11973491$$D View this record in MEDLINE/PubMed |
BookMark | eNo1T11LxDAQDHLifehfkP6B6G42TZrH8_RUOOhLfT7aNMVIv2jqQ_31RtSBZWdnhoXZslU_9I6xBOEOweh7iFCCkAsAAWm8eByEC7ZBqYmnSmQrtgGUxEmRWrNtCB8xkpHSV2yNaDRJgxv2kI-z7_xXOfuhT4Ymmd9dErqybXmwZRv50kcp-PBjPubFnhfLRAkf7Dy5Yfa1u2aXTdkGd_O3d-zt-FQcXvgpf3497E_cCiLgKVhLRgFRpoyUlRRGVGBQZkaJsiZE0ZjGOt1AWkmKhnK1k7V2KGsjpNix29-_42fVufo8Tr4rp-X8X0Z8A6OSTMs |
CitedBy_id | crossref_primary_10_1007_s00259_010_1445_x crossref_primary_10_1002_chem_200305389 crossref_primary_10_1081_RRS_200040939 crossref_primary_10_1016_S0040_4039_03_00221_1 crossref_primary_10_1038_nprot_2006_175 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/00006231-200205000-00010 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1473-5628 |
ExternalDocumentID | 11973491 |
Genre | Journal Article |
GroupedDBID | --- .-D .Z2 0R~ 123 4Q1 4Q2 4Q3 53G 5VS 71W 8L- 8WZ A6W AAAAV AAHPQ AAIQE AARTV AASCR AAYEP ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJIOK AJNWD AJNYG ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK BS7 C45 CAG CGR COF CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C N9A NPM N~M O9- OAG OAH OCUKA ODA OL1 OLG OLV OLW OLZ OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM ZA5 ZFV ZGI ZZMQN |
ID | FETCH-LOGICAL-c2330-50cc39603386944b4292b09148962ad3112f9fce7f05b439146ede4d7e14d9242 |
ISSN | 0143-3636 |
IngestDate | Thu May 23 23:52:18 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2330-50cc39603386944b4292b09148962ad3112f9fce7f05b439146ede4d7e14d9242 |
PMID | 11973491 |
ParticipantIDs | pubmed_primary_11973491 |
PublicationCentury | 2000 |
PublicationDate | 2002-May |
PublicationDateYYYYMMDD | 2002-05-01 |
PublicationDate_xml | – month: 05 year: 2002 text: 2002-May |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Nuclear medicine communications |
PublicationTitleAlternate | Nucl Med Commun |
PublicationYear | 2002 |
SSID | ssj0008367 |
Score | 1.6292528 |
Snippet | The clinical potential of 111In and 90Y labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated Tyr3-octreotide (DOTA-TOC) have been... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 493 |
SubjectTerms | Animals Heterocyclic Compounds, 1-Ring - chemistry Indium Radioisotopes - chemistry Models, Chemical Models, Molecular Molecular Weight Octreotide - analogs & derivatives Octreotide - chemical synthesis Octreotide - chemistry Octreotide - metabolism Rats Receptors, Somatostatin - metabolism |
Title | Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotide |
URI | https://www.ncbi.nlm.nih.gov/pubmed/11973491 |
Volume | 23 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA4-QLyI77f04E0ibZI26XF9IcLuXnbBmyRNAsI-ZN2L_nonTfrwiXopJaGl6TeZTCbzzSB0SjMpEiksBts-xoxbgVXCODY5MdwkBeHccYe7vex2yO7u0_smdKhkl8zVefH6Ja_kP6hCG-DqWLJ_QLZ-KTTAPeALV0AYrr_CuA_zfRyIlNVh__NYjkb4GX69cekIoCmkHLnqDzp48DKjZ3hazGdmOn_U7-KAei61sZzVx-0u3LwhjzS2t56Zx7I6UeNJ7brFS5tX3BlJG2rT117lbmlklm7WcAhVeRlIE9NXOx4pphkNaau9smScYrCfRFubevZwkJq0pRqZr4T4SWX7VMDlugm2psOXxGngu_uI1xaST-MSSnf2SZkv8_Vz74dk2lXXIlrkwinEnnPuhIVb0Myz68NQQ-BXlePzq89zOWfDKz_sS0r7ZLCO1sLGIup4KdlAC2ayiVa6AcstdNEWlmhqIwAlaglLVAuL66yFJWoJyzYa3lwPLm9xKKCBC0JpjNO4KChsUSkVWc6YcqXJFBiITOQZkZqCrW1zWxhu41Q5CjbLjDZMwyRlGiYv2UFLk-nE7KGIxZaoRBOttGRFLmQumDHweMK5UVTuo10_-ocnnyXlofovB9_2HKLVRtSO0LKFaWmOwcabq5MSmTeT-0da |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimization+of+the+small-scale+synthesis+of+DOTA-Tyr3+-octreotide&rft.jtitle=Nuclear+medicine+communications&rft.au=Edreira%2C+M&rft.au=Melendez-Alafort%2C+L&rft.au=Mather%2C+S+J&rft.date=2002-05-01&rft.issn=0143-3636&rft.eissn=1473-5628&rft.volume=23&rft.issue=5&rft.spage=493&rft_id=info:doi/10.1097%2F00006231-200205000-00010&rft_id=info%3Apmid%2F11973491&rft_id=info%3Apmid%2F11973491&rft.externalDocID=11973491 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0143-3636&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0143-3636&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0143-3636&client=summon |